Anaplastic lymphoma kinase (ALK) gene rearrangement defines a distinct molecular subtype of NSCLC and has been found in 3%‐7% of all NSCLC patients.1, 2, 3 Crizotinib, a potent tyrosine kinase inhibitor (TKI) of ALK, ROS1 and MET, was the first molecule inhibitor targeting ALK to be widely used in the clinic.4 Two Phase III trials, PROFILE 1007 and PROFILE 1014 confirmed the benefit of crizotinib over cytotoxic chemotherapy in advanced ALK‐rearranged NSCLC.5, 6. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.